{
  "@context": "aku-v2",
  "@type": "procedure",
  "@id": "wsmg:health-sciences/medicine/hematology/hem-035",
  "metadata": {
    "version": "4.0.0",
    "created": "2026-01-09T01:58:35.000Z",
    "modified": "2026-01-11T02:55:00.000Z",
    "contributors": [
      "copilot-agent",
      "quality-enhancement-agent",
      "quality-agent"
    ],
    "confidence": 0.96,
    "status": "validated",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/hematology",
    "subdomain": "anticoagulation",
    "type": "procedure",
    "difficulty": "intermediate",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Warfarin Therapy",
    "summary": "Warfarin is an oral vitamin K antagonist (VKA) anticoagulant that inhibits synthesis of functional vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (protein C, S). It has a narrow therapeutic index, numerous drug and food interactions, and requires regular INR monitoring. Target INR is 2.0-3.0 for most indications and 2.5-3.5 for mechanical heart valves. While largely replaced by DOACs for many indications, warfarin remains essential for mechanical valves, antiphospholipid syndrome, and severe renal impairment.",
    "key_points": [
      "Mechanism: Inhibits VKORC1 → blocks vitamin K-dependent factor synthesis",
      "Target INR: 2.0-3.0 (most); 2.5-3.5 (mechanical valves)",
      "Onset: 5-7 days for full effect (factor II half-life ~60 hours)",
      "Reversal: Vitamin K (slow), FFP/PCC (rapid), 4-factor PCC preferred",
      "Many drug interactions (CYP2C9, CYP3A4, vitamin K content)",
      "Bridge with heparin when starting - early protein C drop may cause hypercoagulability"
    ],
    "statement": "Warfarin is a vitamin K antagonist anticoagulant requiring INR monitoring, with target 2.0-3.0 for most indications, numerous drug and food interactions, and reversal options including vitamin K and prothrombin complex concentrate.",
    "explanation": {
      "intuition": "Warfarin works by 'starving' the liver of functional vitamin K, preventing proper clotting factor production. It takes days to work because existing clotting factors must die off first. Factor VII goes first (6 hours), but factor II (prothrombin) lasts 60 hours - that's why full anticoagulation takes a week.",
      "key_insight": "Protein C (anticoagulant) has a shorter half-life than prothrombin (procoagulant). When starting warfarin, protein C drops before factor II, creating a transient hypercoagulable state. This is why we bridge with heparin and why warfarin alone can cause skin necrosis in protein C deficiency.",
      "technical_details": "Warfarin inhibits VKORC1 (vitamin K epoxide reductase), preventing recycling of vitamin K to its reduced active form. Metabolism primarily via CYP2C9 (major) and CYP3A4 (minor). S-warfarin is 3-5× more potent than R-warfarin. VKORC1 and CYP2C9 genetic polymorphisms affect dosing. Half-life 20-60 hours; peak effect 36-72 hours."
    },
    "definitions_glossary": {
      "warfarin": "Oral vitamin K antagonist anticoagulant inhibiting VKORC1",
      "VKORC1": "Vitamin K epoxide reductase complex 1; warfarin's molecular target",
      "INR": "International Normalized Ratio; standardized PT measurement for warfarin monitoring",
      "vitamin_K_antagonist": "Drug class blocking vitamin K-dependent factor synthesis",
      "therapeutic_index": "Ratio of toxic to therapeutic dose; narrow for warfarin",
      "bridging_anticoagulation": "Temporary use of heparin when starting/stopping warfarin",
      "PCC": "Prothrombin complex concentrate; contains II, VII, IX, X for rapid reversal",
      "CYP2C9": "Cytochrome P450 enzyme metabolizing S-warfarin",
      "protein_C": "Vitamin K-dependent anticoagulant; early drop causes hypercoagulability",
      "supratherapeutic_INR": "INR above target range; increased bleeding risk",
      "warfarin_skin_necrosis": "Rare complication from protein C depletion; more common in protein C deficiency",
      "time_in_therapeutic_range": "TTR; quality measure for warfarin management"
    }
  },
  "clinical_features": {
    "pharmacology": {
      "mechanism": {
        "target": "VKORC1 (vitamin K epoxide reductase complex 1)",
        "effect": "Blocks vitamin K recycling → reduced γ-carboxylation",
        "affected_factors": ["II", "VII", "IX", "X", "Protein C", "Protein S"],
        "half_lives": {
          "factor_VII": "6 hours",
          "protein_C": "8 hours",
          "factor_IX": "24 hours",
          "factor_X": "36 hours",
          "factor_II": "60 hours"
        }
      },
      "pharmacokinetics": {
        "absorption": ">90% oral bioavailability",
        "protein_binding": "99% albumin-bound",
        "metabolism": "CYP2C9 (S-warfarin, active), CYP3A4 (R-warfarin)",
        "half_life": "20-60 hours (variable)",
        "onset": "24-72 hours INR rise; 5-7 days full anticoagulation"
      },
      "genetics": {
        "VKORC1_polymorphisms": "Affect warfarin sensitivity",
        "CYP2C9_polymorphisms": "Affect metabolism (*2, *3 alleles reduce dose)",
        "clinical_use": "Pharmacogenetic dosing can reduce adverse events"
      }
    },
    "indications": {
      "first_line": {
        "mechanical_heart_valves": "DOACs contraindicated",
        "antiphospholipid_syndrome": "DOACs not recommended",
        "severe_CKD": "CrCl <15-25 mL/min; DOAC data limited"
      },
      "alternative_to_DOACs": {
        "atrial_fibrillation": "When DOACs contraindicated or not tolerated",
        "VTE": "Alternative when cost or access is barrier",
        "valvular_AFib": "Moderate-severe mitral stenosis"
      }
    },
    "dosing_and_monitoring": {
      "initiation": {
        "loading_not_recommended": "High-dose loading increases bleeding",
        "typical_start": "5 mg daily (2.5 mg if elderly, low weight, liver disease)",
        "bridging": "Concurrent heparin/LMWH until INR therapeutic × 24 hours"
      },
      "INR_targets": {
        "most_indications": "2.0-3.0 (AFib, VTE, tissue valves)",
        "mechanical_valves": "2.5-3.5 (higher for mitral, older valves)"
      },
      "monitoring_frequency": {
        "initial": "Daily or every other day until stable",
        "stable": "Every 4 weeks",
        "TTR_goal": ">65-70% time in therapeutic range"
      }
    },
    "drug_interactions": {
      "increased_INR": {
        "antibiotics": ["Metronidazole", "Fluoroquinolones", "Macrolides", "TMP-SMX", "Fluconazole"],
        "other_drugs": ["Amiodarone", "Statins", "SSRIs", "Acetaminophen (chronic high dose)"]
      },
      "decreased_INR": {
        "CYP_inducers": ["Rifampin", "Carbamazepine", "Phenytoin", "St. John's wort"],
        "vitamin_K_sources": "High intake of green leafy vegetables"
      },
      "dietary": {
        "vitamin_K_foods": ["Kale", "Spinach", "Broccoli", "Brussels sprouts"],
        "advice": "Maintain consistent intake rather than avoiding"
      }
    },
    "adverse_effects": {
      "bleeding": {
        "major_bleeding": "1-3% per year on therapeutic anticoagulation",
        "intracranial_hemorrhage": "Higher risk than DOACs",
        "GI_bleeding": "Common site"
      },
      "skin_necrosis": {
        "mechanism": "Protein C depletion before factor II depletion",
        "risk_factors": "Protein C or S deficiency; loading doses",
        "prevention": "Bridge with heparin; avoid loading doses"
      },
      "purple_toe_syndrome": "Rare; cholesterol microembolization",
      "teratogenicity": "Warfarin embryopathy; avoid in pregnancy (especially weeks 6-12)"
    },
    "reversal": {
      "non_urgent": {
        "hold_warfarin": "For INR 4.5-10 without bleeding",
        "oral_vitamin_K": "1-2.5 mg if INR very high or higher risk patient"
      },
      "urgent_no_bleeding": {
        "IV_vitamin_K": "2.5-5 mg slow infusion",
        "onset": "6-24 hours"
      },
      "life_threatening_bleeding": {
        "4_factor_PCC": "25-50 units/kg based on INR (preferred)",
        "FFP": "10-15 mL/kg if PCC unavailable (larger volume)",
        "plus_vitamin_K": "10 mg IV (sustains reversal)",
        "avoid": "rFVIIa alone (doesn't provide all factors)"
      },
      "reversal_agents_comparison": {
        "vitamin_K": "Slow (6-24h) but sustained",
        "FFP": "Fast but transient, large volume",
        "4F_PCC": "Fast, small volume, preferred for major bleeding"
      }
    }
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Warfarin Therapy"
    },
    "altLabel": [
      {"@language": "en", "@value": "Coumadin Therapy"},
      {"@language": "en", "@value": "VKA Therapy"},
      {"@language": "en", "@value": "Vitamin K Antagonist Anticoagulation"}
    ],
    "definition": {
      "@language": "en",
      "@value": "Oral anticoagulation using vitamin K antagonist warfarin, requiring INR monitoring and dose adjustment"
    },
    "notation": "hem-035",
    "scopeNote": {
      "@language": "en",
      "@value": "Essential for mechanical valves and antiphospholipid syndrome"
    }
  },
  "relationships": {
    "skos:broader": [
      {
        "@id": "wsmg:health-sciences/medicine/hematology/anticoagulation",
        "skos:prefLabel": "Anticoagulation"
      }
    ],
    "skos:related": [
      {
        "@id": "wsmg:health-sciences/medicine/hematology/hem-033",
        "skos:prefLabel": "Vitamin K Deficiency Coagulopathy"
      },
      {
        "@id": "wsmg:health-sciences/medicine/hematology/hem-036",
        "skos:prefLabel": "DOAC Therapy"
      }
    ],
    "owl:sameAs": [
      "http://dbpedia.org/resource/Warfarin"
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "372756006",
      "uri": "http://snomed.info/id/372756006",
      "description": "Warfarin"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "RxNorm",
      "codeValue": "11289",
      "uri": "http://rxnav.nlm.nih.gov/REST/rxcui/11289",
      "description": "Warfarin"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "MeSH",
      "codeValue": "D014859",
      "uri": "http://id.nlm.nih.gov/mesh/D014859",
      "description": "Warfarin"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Explain warfarin's mechanism of action via VKORC1 inhibition",
      "Select appropriate INR target for different indications",
      "Identify major drug and food interactions",
      "Manage supratherapeutic INR with appropriate reversal strategy",
      "Recognize warfarin skin necrosis risk in protein C deficiency"
    ],
    "clinical_pearls": [
      "Full anticoagulation takes 5-7 days - factor II half-life is 60 hours",
      "Bridge with heparin: protein C drops before factor II → transient hypercoagulability",
      "Target 2.5-3.5 for mechanical valves; 2.0-3.0 for everything else",
      "4-factor PCC preferred over FFP for major bleeding reversal",
      "Maintain consistent vitamin K intake - don't need to avoid greens"
    ],
    "board_yield": "HIGH",
    "estimated_time": "25min",
    "target_audience": [
      "medical_students",
      "internal_medicine_residents",
      "pharmacists"
    ],
    "common_misconceptions": [
      "Warfarin works immediately - takes 5-7 days for full effect",
      "Avoid all vitamin K foods - just maintain consistent intake",
      "Loading doses speed anticoagulation safely - they increase bleeding and necrosis risk",
      "FFP is best for reversal - 4-factor PCC is preferred"
    ]
  },
  "prerequisites": [
    {
      "@id": "wsmg:health-sciences/medicine/hematology/coagulation-cascade",
      "skos:prefLabel": "Coagulation Cascade"
    },
    {
      "@id": "wsmg:health-sciences/medicine/hematology/hem-033",
      "skos:prefLabel": "Vitamin K Deficiency Coagulopathy"
    }
  ],
  "related_concepts": [
    "vitamin K",
    "INR",
    "VKORC1",
    "prothrombin complex concentrate",
    "mechanical heart valves"
  ],
  "evidence": {
    "citations": [
      {
        "authors": "Ageno W, Gallus AS, Wittkowsky A, et al.",
        "title": "Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed",
        "journal": "Chest",
        "year": 2012,
        "volume": "141",
        "pages": "e52S-e88S",
        "doi": "10.1378/chest.11-2292"
      }
    ],
    "confidence_rationale": "Well-established pharmacology and extensive clinical experience"
  },
  "provenance": {
    "verification_status": "verified",
    "last_verified": "2026-01-11T02:55:00.000Z",
    "sources": [
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill, 2022.",
        "type": "textbook",
        "year": 2022,
        "isbn": "978-1264268504",
        "relevance": "Standard medical reference"
      },
      {
        "source": "CHEST Guidelines on Antithrombotic Therapy, 2012.",
        "type": "guideline",
        "year": 2012,
        "relevance": "Clinical guidelines"
      }
    ]
  },
  "quality_assessment": {
    "content_quality_score": 0.95,
    "completeness": 0.96,
    "accuracy": 0.96,
    "clarity": 0.95,
    "clinical_relevance": 0.97,
    "last_assessed": "2026-01-11T02:55:00.000Z"
  },
  "owl:sameAs": "http://dbpedia.org/resource/Warfarin",
  "skos:exactMatch": "http://www.wikidata.org/entity/Q424915"
}